Michael Harvey Davidson
CEO, President & Executive DirectorDr. Michael Harvey Davidson, M.D., FACC., FNLA, serves as Director at Nanophoria S.R.L. since January 2024. Dr. Davidson is a Co-Founder and Chief Scientific Officer of TROFI NUTRITIONALS, INC. He serves as Director at Jocasta Neuroscience, Inc. and serves as its Chair of the Board. Dr. Davidson is Independent Director of BioAge Labs, Inc. from March 2024. Dr. Davidson is Co-Founder, Executive Chairman of the Board of Directors and Secretary of SonoThera, Inc. He had been Non-Executive Director at Silence Therapeutics plc since January 2021 until August 11, 2025. He served as Clinical Research Advisor at Circulogene Theranostics, Inc. until 2021. Dr. Davidson serves as Independent Director at Tenax Therapeutics Inc since February 25, 2021. Dr. Davidson has been Chief Executive Officer and Executive Board Member at Frazier Lifesciences Acquisition Corporation (formerly known as NewAmsterdam Pharma Company N.V. (formerly known as NewAmsterdam Pharma B.V.)) since joining in August 2020 and serves as President since November 23, 2022 and served as its Director until August 14, 2025. Dr. Davidson was a Co-founder of Corvidia Therapeutics, Inc., which sold to Novo Nordisk in July 2020 and was its Chief Scientific Officer from March 29, 2018 to July 2020. Dr. Davidson was Director of Lisata Therapeutics, Inc. (formerly known as Caladrius Biosciences, Inc.) since July 28, 2020 until September 15, 2022. Dr. Davidson serves as Director at Inositec AG, Sonogene LLC and PHP Precision Med. Dr. Davidson served as Director at Cerenis Therapeutics/Abionyx Therapeutics from January 2015 through September 2019. Dr. Davidson served as Chief Executive Officer of Corvidia Therapeutics, Inc. until March 29, 2018. Dr. Davidson was a Co-founder and Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008 and served as its Executive Vice President since December 2008. Dr. Davidson also serves as Clinical Professor and Director of the Lipid Clinic at the University of Chicago Pritzker School of Medicine. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs and omega-3 fatty acids. Dr. Davidson is a nationally recognized expert in lipidology and has been named one of "The Best Doctors in America" by Best Doctors Inc. Dr. Davidson is board-certified in internal medicine, cardiology and clinical lipidology. Dr. Davidson served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson is a Clinical Professor and Director of Preventative Cardiology at the University of Chicago Medical Center. Dr. Davidson is Founder, President and Chief Executive Officer of Chicago Center for Clinical Research. Dr. Davidson served as an Executive Medical Director of Protocare Trials, Radiant Development and Radiant Research, Inc. He served as a Medical Advisor at Pinpoint MD, LLC. Dr. Davidson has been the Chairman of Scientific Advisory Board of Vital Living, Inc. since March 2002. He served as a Director of Corvidia Therapeutics, Inc. He was an Independent Director at ABIONYX Pharma SA from January 16, 2015 to September 6,2019. He serves as a Member of Expert Advisory Board of Private Health Management, Inc. Dr. Davidson is a board-certified cardiologist and serves as Member of Medical Advisory Board at PreEmptive Meds, Inc. He is also an associate professor in the Department of Medicine and Director of the Preventive Cardiology Center at Rush-Presbyterian-St. Lukes Medical Center, where he directs the multiple risk factor reduction lipid clinic. He serves as a Member of Scientific Advisory Board of Vital Living Inc. He serves as a Member of Medical Advisory Panel at LipoScience, Inc. Dr. Davidson serves as a Member of Cardiovascular Scientific Advisory Board of Veloxis Pharmaceuticals A/S. He served as Medical & Scientific Advisor and Member of Scientific Board of Advisors at WellnessFX, Inc. As a prolific author and lecturer on lipid disorders, nutrition and arteriosclerosis, Dr. Davidson has coordinated over 700 clinical trials in areas of preventive cardiology and has published more than 200 articles in medical journals, including the Journal of the American Medical Association, the Journal of the American College of Cardiology, Circulation and Arteriosclerosis. He is a fellow of the American College of Cardiology and the American College of Chest Physicians. He is the Chairman of Scientific Advisory Board at ABIONYX Pharma SA. He holds a BA/MS from Northwestern University. He also holds a Medical degree from Ohio State University School of Medicine in Columbus and has completed a cardiology fellowship at Rush-Presbyterian-St. Lukes Medical Center in Chicago. He served as a Member of Medical Advisory Board at Atherotech, Inc.
Positions
- Company NameNewAmsterdam Pharma Company N.V.Stock CodeNAMSPositionCEO, President & Executive DirectorRelated SecuritiesColleagues
- WHWilliam H. LewisIndependent Chairman of Board of Directors
- JJJohannes Jacob Pieter KasteleinFounder, Chief Scientific Officer, Member of Executive Board & Director
- MAMayur Amrat SomaiyaChief Financial Officer
- RWRobert W. GunningPrincipal Accounting Officer, VP & Controller
- MPMatthew PhilippeExecutive VP & Head of Investor Relations
- MCMark C. McKennaIndependent Non-Executive Vice Chairman
- JWJohn W. SmitherIndependent Director
